NO312125B1 - Virussikkert trombin, farmasöytisk preparat inneholdende dette samt anvendelse ved fremstilling av et farmasöytisk preparateller et diagnostisk preparat - Google Patents
Virussikkert trombin, farmasöytisk preparat inneholdende dette samt anvendelse ved fremstilling av et farmasöytisk preparateller et diagnostisk preparat Download PDFInfo
- Publication number
- NO312125B1 NO312125B1 NO19924229A NO924229A NO312125B1 NO 312125 B1 NO312125 B1 NO 312125B1 NO 19924229 A NO19924229 A NO 19924229A NO 924229 A NO924229 A NO 924229A NO 312125 B1 NO312125 B1 NO 312125B1
- Authority
- NO
- Norway
- Prior art keywords
- thrombin
- preparation
- virus
- prothrombin
- plasma fraction
- Prior art date
Links
- 108090000190 Thrombin Proteins 0.000 title claims abstract description 48
- 229960004072 thrombin Drugs 0.000 title claims abstract description 46
- 238000002360 preparation method Methods 0.000 title claims description 8
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 7
- 238000004519 manufacturing process Methods 0.000 title claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 108010094028 Prothrombin Proteins 0.000 claims abstract description 37
- 102100027378 Prothrombin Human genes 0.000 claims abstract description 32
- 229940039716 prothrombin Drugs 0.000 claims abstract description 32
- 239000012678 infectious agent Substances 0.000 claims abstract description 8
- 241001465754 Metazoa Species 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims description 8
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 7
- 229910001424 calcium ion Inorganic materials 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- 108010018823 anti-inhibitor coagulant complex Proteins 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 229940105776 factor viii inhibitor bypassing activity Drugs 0.000 claims description 5
- 230000015271 coagulation Effects 0.000 claims description 4
- 238000005345 coagulation Methods 0.000 claims description 4
- 239000007858 starting material Substances 0.000 claims description 4
- 150000003904 phospholipids Chemical class 0.000 claims description 3
- 238000001042 affinity chromatography Methods 0.000 claims description 2
- 238000004255 ion exchange chromatography Methods 0.000 claims description 2
- 239000007790 solid phase Substances 0.000 claims 1
- 230000004913 activation Effects 0.000 abstract description 10
- 238000010438 heat treatment Methods 0.000 abstract description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 210000002381 plasma Anatomy 0.000 description 6
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 5
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 5
- 239000003114 blood coagulation factor Substances 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 108010074860 Factor Xa Proteins 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 238000011109 contamination Methods 0.000 description 4
- 108010049003 Fibrinogen Proteins 0.000 description 3
- 102000008946 Fibrinogen Human genes 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229940012952 fibrinogen Drugs 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 108010000499 Thromboplastin Proteins 0.000 description 2
- 102000002262 Thromboplastin Human genes 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 235000011148 calcium chloride Nutrition 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000011026 diafiltration Methods 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 108010014806 prothrombinase complex Proteins 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 108010014172 Factor V Proteins 0.000 description 1
- 101001038021 Lonomia obliqua Lopap Proteins 0.000 description 1
- 102000006833 Multifunctional Enzymes Human genes 0.000 description 1
- 108010047290 Multifunctional Enzymes Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 208000031737 Tissue Adhesions Diseases 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 229940019700 blood coagulation factors Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 108010074164 cyclohexylglycyl-alanyl-arginine-4-nitroanilide Proteins 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000011066 ex-situ storage Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6429—Thrombin (3.4.21.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21005—Thrombin (3.4.21.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Amplifiers (AREA)
- Revetment (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT0218391A AT398079B (de) | 1991-11-04 | 1991-11-04 | Präparation mit thrombinaktivität sowie verfahren zu ihrer herstellung |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO924229D0 NO924229D0 (no) | 1992-11-03 |
| NO924229L NO924229L (no) | 1993-05-05 |
| NO312125B1 true NO312125B1 (no) | 2002-03-25 |
Family
ID=3529491
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19924229A NO312125B1 (no) | 1991-11-04 | 1992-11-03 | Virussikkert trombin, farmasöytisk preparat inneholdende dette samt anvendelse ved fremstilling av et farmasöytisk preparateller et diagnostisk preparat |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US5714370A (fi) |
| EP (1) | EP0541507B1 (fi) |
| JP (1) | JP2572513B2 (fi) |
| AT (2) | AT398079B (fi) |
| AU (1) | AU645715B2 (fi) |
| CA (1) | CA2081703C (fi) |
| CZ (1) | CZ281502B6 (fi) |
| DE (1) | DE59209922D1 (fi) |
| DK (1) | DK0541507T3 (fi) |
| ES (1) | ES2165355T3 (fi) |
| FI (1) | FI104378B (fi) |
| HR (1) | HRP921171B1 (fi) |
| HU (1) | HU213867B (fi) |
| MX (1) | MX9206303A (fi) |
| NO (1) | NO312125B1 (fi) |
| PL (1) | PL170156B1 (fi) |
| SI (1) | SI9200299B (fi) |
| SK (1) | SK330992A3 (fi) |
| YU (1) | YU96192A (fi) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT402891B (de) * | 1991-06-20 | 1997-09-25 | Immuno Ag | Verfahren zur herstellung eines inaktivierten blutproduktes |
| DE4137996A1 (de) * | 1991-11-19 | 1993-05-27 | Behringwerke Ag | Verfahren zur herstellung eines virussicheren thrombinkonzentrates |
| AT399818B (de) * | 1992-04-24 | 1995-07-25 | Immuno Ag | Verfahren zur herstellung einer hochgereinigten virussicheren faktor viii-präparation |
| JP3133338B2 (ja) * | 1992-12-16 | 2001-02-05 | イムノ・アクチエンゲゼルシャフト | ウイルス的に安全な生物学的組成物の調製方法 |
| DE4320294A1 (de) * | 1993-06-18 | 1994-12-22 | Immuno Ag | Verwendung von humanem Protein C zur Verhinderung und Behandlung von Thrombozytenablagerungen |
| JPH07308190A (ja) * | 1994-05-18 | 1995-11-28 | Green Cross Corp:The | トロンビンの製造方法 |
| US5506127A (en) * | 1994-09-21 | 1996-04-09 | Proba; Zbigniew | Therapeutic grade thrombin produced by chromatography |
| GB9503750D0 (en) * | 1995-02-24 | 1995-04-12 | Common Services Agency | Thrombin preparation |
| AT404597B (de) | 1995-11-24 | 1998-12-28 | Immuno Ag | Verfahren zur herstellung von proteinen |
| JP3944267B2 (ja) * | 1996-08-09 | 2007-07-11 | 財団法人化学及血清療法研究所 | プロトロンビンの活性化方法および該方法に基づくトロンビンの製造方法 |
| US8603511B2 (en) | 1996-08-27 | 2013-12-10 | Baxter International, Inc. | Fragmented polymeric compositions and methods for their use |
| US7435425B2 (en) | 2001-07-17 | 2008-10-14 | Baxter International, Inc. | Dry hemostatic compositions and methods for their preparation |
| US6066325A (en) * | 1996-08-27 | 2000-05-23 | Fusion Medical Technologies, Inc. | Fragmented polymeric compositions and methods for their use |
| US8303981B2 (en) | 1996-08-27 | 2012-11-06 | Baxter International Inc. | Fragmented polymeric compositions and methods for their use |
| AT405608B (de) * | 1997-04-08 | 1999-10-25 | Immuno Ag | Verfahren zur inaktivierung von pathogenen, insbesondere von viren, in einem biologischen material |
| AT405485B (de) | 1997-05-28 | 1999-08-25 | Immuno Ag | Eine das vwf-propeptid enthaltende pharmazeutische präparation |
| WO2001000667A2 (en) * | 1999-06-29 | 2001-01-04 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-thrombin peptide from anopheles albimanus salivary gland |
| US7795218B2 (en) | 2001-04-12 | 2010-09-14 | Bioaxone Therapeutique Inc. | ADP-ribosyl transferase fusion variant proteins |
| GB0216002D0 (en) * | 2002-07-10 | 2002-08-21 | Nat Blood Authority | Process and composition |
| US8834864B2 (en) * | 2003-06-05 | 2014-09-16 | Baxter International Inc. | Methods for repairing and regenerating human dura mater |
| US7927626B2 (en) | 2003-08-07 | 2011-04-19 | Ethicon, Inc. | Process of making flowable hemostatic compositions and devices containing such compositions |
| MX2008014847A (es) * | 2006-05-31 | 2009-04-30 | Baxter Int | Metodo para crecimiento interno en la celula dirigido y regeneracion controlada de los tejidos en la cirugia espinal. |
| TWI436793B (zh) | 2006-08-02 | 2014-05-11 | Baxter Int | 快速作用之乾密封膠及其使用和製造方法 |
| CN101842122B (zh) | 2007-10-30 | 2013-12-25 | 巴克斯特国际公司 | 再生性生物功能胶原生物基质用于治疗内脏或腔壁缺损的应用 |
| JP5569398B2 (ja) | 2008-02-29 | 2014-08-13 | フェッローサン メディカル ディバイス エー／エス | 止血および／または創傷治癒を促進するための装置 |
| KR101678241B1 (ko) | 2008-12-11 | 2016-11-21 | 백스터 인터내셔널 인코포레이티드 | 피브리노겐 및 황산화 다당류 기재의 제제 |
| KR101105026B1 (ko) * | 2009-04-06 | 2012-01-16 | 김기영 | 다방향 굴절형 핸드 그라인더 |
| US9039783B2 (en) | 2009-05-18 | 2015-05-26 | Baxter International, Inc. | Method for the improvement of mesh implant biocompatibility |
| PT2442835E (pt) | 2009-06-16 | 2015-03-23 | Baxter Healthcare Sa | Esponja hemostática |
| KR101811070B1 (ko) | 2009-12-16 | 2017-12-20 | 백스터 인터내셔널 인코포레이티드 | 지혈 스폰지 |
| SA111320355B1 (ar) | 2010-04-07 | 2015-01-08 | Baxter Heathcare S A | إسفنجة لايقاف النزف |
| KR101957625B1 (ko) | 2010-06-01 | 2019-03-12 | 백스터 인터내셔널 인코포레이티드 | 건조 및 안정한 지혈 조성물의 제조 방법 |
| US9084728B2 (en) | 2010-06-01 | 2015-07-21 | Baxter International Inc. | Process for making dry and stable hemostatic compositions |
| EP2575776B1 (en) | 2010-06-01 | 2018-05-30 | Baxter International Inc | Process for making dry and stable hemostatic compositions |
| JP6195569B2 (ja) | 2011-10-11 | 2017-09-13 | バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ | 止血組成物 |
| CA2851338C (en) | 2011-10-11 | 2019-11-05 | Baxter International Inc. | Hemostatic compositions |
| DK2771027T3 (en) | 2011-10-27 | 2015-11-02 | Baxter Int | hemostatic compositions |
| WO2013091895A1 (en) * | 2011-12-23 | 2013-06-27 | Merz Pharma Gmbh & Co. Kgaa | Novel method for the manufacturing of di-chain proteins for use in humans |
| CA2865349C (en) | 2012-03-06 | 2021-07-06 | Ferrosan Medical Devices A/S | Pressurized container containing haemostatic paste |
| CA2874290C (en) | 2012-06-12 | 2020-02-25 | Ferrosan Medical Devices A/S | Dry haemostatic composition |
| CN105358071B (zh) | 2013-06-21 | 2018-07-31 | 弗罗桑医疗设备公司 | 真空膨胀的干组合物和用于保留该干组合物的注射器 |
| CA2928963C (en) | 2013-12-11 | 2020-10-27 | Ferrosan Medical Devices A/S | Dry composition comprising an extrusion enhancer |
| WO2016058612A1 (en) | 2014-10-13 | 2016-04-21 | Ferrosan Medical Devices A/S | Dry composition for use in haemostasis and wound healing |
| EP3237041B1 (en) | 2014-12-24 | 2020-01-29 | Ferrosan Medical Devices A/S | Syringe for retaining and mixing first and second substances |
| BR112017027695A2 (pt) | 2015-07-03 | 2018-09-04 | Ferrosan Medical Devices As | seringa para retenção e mistura de primeira e segunda substâncias |
| CN110382011A (zh) | 2017-03-09 | 2019-10-25 | 巴克斯特国际公司 | 溶剂沉积系统和方法 |
| MX2020011866A (es) | 2018-05-09 | 2021-01-20 | Ferrosan Medical Devices As | Metodo para preparar una composicion hemostatica. |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT350726B (de) * | 1976-08-30 | 1979-06-11 | Immuno Ag | Verfahren zur herstellung einer blut- gerinnungsfoerdernden praeperation aus menschlichem blutplasma |
| DE2902158A1 (de) * | 1979-01-20 | 1980-07-31 | Biotest Serum Institut Gmbh | Verfahren zur herstellung von fibrinogen, einem die gerinnungsfaktoren ii, vii, ix und x enthaltenden prothrombinkomplex, antithrombin iii und einer loesung von lagerstabilen serumproteinen |
| US4357321A (en) * | 1980-01-28 | 1982-11-02 | Baxter Travenol Laboratories, Inc. | Method and composition for treating clotting factor inhibitors |
| DE3019612A1 (de) * | 1980-05-22 | 1981-11-26 | Boehringer Mannheim Gmbh, 6800 Mannheim | Stabilisiertes thrombinpraeparat |
| US4404132A (en) * | 1980-05-27 | 1983-09-13 | Cutter Laboratories, Inc. | Blood coagulation promoting product |
| US4364861A (en) * | 1980-05-27 | 1982-12-21 | Cutter Laboratories, Inc. | Blood-coagulation-promoting products and methods of preparing them |
| AT368883B (de) * | 1980-07-22 | 1982-11-25 | Immuno Ag | Verfahren zur herstellung einer neuen blutgerinnungsfoerdernden praeparation auf basis von humanproteinen |
| US4480029A (en) * | 1981-04-27 | 1984-10-30 | Baxter Travenol Laboratories, Inc. | Biological indicators and their use |
| US4495278A (en) * | 1981-04-27 | 1985-01-22 | Baxter Travenol Laboratories, Inc. | Process for making novel blood clotting enzyme compositions |
| US4764369A (en) * | 1983-07-14 | 1988-08-16 | New York Blood Center Inc. | Undenatured virus-free biologically active protein derivatives |
| AT389815B (de) * | 1984-03-09 | 1990-02-12 | Immuno Ag | Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten |
| AT385657B (de) * | 1984-03-09 | 1988-05-10 | Immuno Ag | Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten |
| US4613501A (en) * | 1984-12-21 | 1986-09-23 | New York Blood Center, Inc. | Inactivation of viruses in labile blood derivatives |
| US4673733A (en) * | 1985-04-11 | 1987-06-16 | Sudhish Chandra | Treatment of biological and pharmaceutical products adsorbed on a solid phase with virus and pyrogen inactivating agents |
| JPS63243032A (ja) * | 1987-03-27 | 1988-10-07 | Green Cross Corp:The | トロンビンの加熱処理方法 |
| DE3843126C3 (de) * | 1988-12-22 | 1994-10-06 | Octapharma Ag | Verfahren zur Herstellung eines hochreinen Thrombinkonzentrates |
| EP0378208B2 (en) * | 1989-01-13 | 2003-01-15 | Mitsubishi Pharma Corporation | Production method for protein-containing composition |
| IE73210B1 (en) * | 1990-01-24 | 1997-05-07 | Warner Lambert Co | Process for the production of thrombin and high purity thrombin preparation thereby obtained |
| ES2131504T3 (es) * | 1990-02-20 | 1999-08-01 | Baxter Int | Trombina humana purificada viricamente segura. |
| FR2679251B1 (fr) * | 1991-07-18 | 1993-11-12 | Nord Assoc Essor Transfusion San | Procede de preparation d'un concentre de thrombine humaine destine a un usage therapeutique. |
| DE4137996A1 (de) * | 1991-11-19 | 1993-05-27 | Behringwerke Ag | Verfahren zur herstellung eines virussicheren thrombinkonzentrates |
-
1991
- 1991-11-04 AT AT0218391A patent/AT398079B/de not_active IP Right Cessation
-
1992
- 1992-10-27 AU AU27361/92A patent/AU645715B2/en not_active Ceased
- 1992-10-27 HU HU9203366A patent/HU213867B/hu not_active IP Right Cessation
- 1992-10-29 CA CA002081703A patent/CA2081703C/en not_active Expired - Lifetime
- 1992-11-02 DE DE59209922T patent/DE59209922D1/de not_active Revoked
- 1992-11-02 ES ES92890232T patent/ES2165355T3/es not_active Expired - Lifetime
- 1992-11-02 DK DK92890232T patent/DK0541507T3/da active
- 1992-11-02 AT AT92890232T patent/ATE206757T1/de not_active IP Right Cessation
- 1992-11-02 EP EP92890232A patent/EP0541507B1/de not_active Revoked
- 1992-11-02 HR HRA2183/91A patent/HRP921171B1/xx not_active IP Right Cessation
- 1992-11-03 MX MX9206303A patent/MX9206303A/es unknown
- 1992-11-03 NO NO19924229A patent/NO312125B1/no not_active IP Right Cessation
- 1992-11-03 PL PL92296460A patent/PL170156B1/pl not_active IP Right Cessation
- 1992-11-04 SK SK3309-92A patent/SK330992A3/sk unknown
- 1992-11-04 FI FI924975A patent/FI104378B/fi not_active IP Right Cessation
- 1992-11-04 JP JP4294962A patent/JP2572513B2/ja not_active Expired - Fee Related
- 1992-11-04 YU YU96192A patent/YU96192A/sh unknown
- 1992-11-04 SI SI9200299A patent/SI9200299B/sl not_active IP Right Cessation
- 1992-11-04 CZ CS923309A patent/CZ281502B6/cs not_active IP Right Cessation
-
1995
- 1995-06-01 US US08/458,082 patent/US5714370A/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO312125B1 (no) | Virussikkert trombin, farmasöytisk preparat inneholdende dette samt anvendelse ved fremstilling av et farmasöytisk preparateller et diagnostisk preparat | |
| JP4101309B2 (ja) | 治療的用途のためのヒトトロンビン濃厚液の製造法 | |
| JP2002518411A (ja) | 薬学的第ｖｉｉ因子調製物 | |
| JPS6236493B2 (fi) | ||
| AU737566B2 (en) | An immunotolerant prothrombin complex preparation | |
| EP0782616A1 (en) | Therapeutic grade thrombin production and products | |
| CA2105282C (en) | Preparation of factor ix | |
| NO307473B1 (no) | Fremgangsmõte for fremstilling av et pasteurisert trombinkonsentrat | |
| US5393666A (en) | Method of activating prothrombin | |
| JP3944267B2 (ja) | プロトロンビンの活性化方法および該方法に基づくトロンビンの製造方法 | |
| JPH07308190A (ja) | トロンビンの製造方法 | |
| US6168938B1 (en) | Method for the production of thrombin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |